Please login to the form below
ATMPs
This page shows the latest ATMPs news and features for those working in and with pharma, biotech and healthcare.
Boehringer spends €1.18bn to acquire NBE-Therapeutics
Merk &Kollegen, which will give it access to the latter’s advanced therapy medicinal products (ATMP)-based immuno-oncology therapies. ... Merk &Kollegen’s manufacturing site, which is involved in ATMP-based cancer immunology treatments.
Latest news
-
Europe urged to adapt faster to gene therapy challenges
ATMP-dedicated funds, allowing health systems to invest in ATMPs that offer the potential for long-term benefits. ... Expansion of opportunities for early dialogue between ATMP developers and payers, supported by increased EU funding.
-
Europe responding to gene therapy challenge, but picture remains fragmented
Tamir Singer. Tamir Singer, head of commercial development, specialised commissioning, NHS England said his organisation was increasingly interested in integrating real world evidence into reimbursement deals for ATMPs. ... Chiesi’s Holoclar is another
-
FDA expecting boom in cell and gene therapies
Pledges clampdown on developers working outside regulations
-
MedCity sets up advanced therapy research network
These therapies – collectively known as advanced therapy medicinal products (ATMP) in European regulatory parlance – are relatively new entrants onto the market but are expected to grow quickly to reach a value ... Other initiatives in ATMP are
-
Novartis: pipeline will generate 60 filings in three years
Advanced therapy medicinal products. Novartis’ push into advanced therapy medicinal products (ATMP) such as cell and gene therapies means it now has 13 candidates in clinical development with another nine due
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
EU cross-border healthcare
The reality for many patients and their families is sobering. Gene therapies and other Advanced Therapy Medicinal Products (ATMPs) require specialist treatment processes. ... The current challenges patients face when seeking access to an approved gene
-
The European Medicines Agency: PRIME’d for access?
177 requests for eligibility, or 8 a month on average. 71 requests have been chemical products, 43 biological, 42 ATMPs with the last 13 classed as ‘other’.
-
Europe vs the US: New drug product approvals
Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the
-
Gathering pace: adaptive pathways
Applications included six advanced-therapy medicinal products (ATMPs) and 12 orphan drugs, while 14 of them were for new cancer therapies. ... The first of these in-depth discussions, on the quality aspects of an ATMP, took place in December 2014, with
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
advanced therapy medicinal products (ATMPs).
-
Dr Gopalan Narayanan joins VCLS
Founder and CEO of VCLS Dr Emmanuelle Voisin said: “The appointment of Dr Narayanan further enhances VCLS’s ability to support biotechnology companies throughout ATMP research and development, and lead scientific
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
EU Pharmaceutical Strategy Roadmap
In ATMPs, the need for surveillance and long-term follow-up of patients will need to be addressed. ... And we continue to see the pricing and reimbursement challenges faced by ATMPs.
-
Hanover Communications
As discussed in a recent article, the next few years will define the future of life sciences and especially the regulation of breakthrough advanced therapy medicinal products (ATMPs) and orphan medicinal ... ATMPs and OMPs.
-
Spotlight interview: 15 minutes on healthcare communications in gene therapy
It is an exciting and interesting time with many ATMPs being launched over the next few years. ... 3. WHAT EXPERIENCE HAS OPEN HEALTH HAD WITH ATMP COMMERCIALISATION? We have worked with around half of the ATMPs that have already been launched globally.
-
Generating data on long-term outcomes with gene and other advanced therapies
From a patient perspective, and if ATMPs fulfil their promise, post-treatment disease symptoms may be considerably reduced or even non-existent. ... From a health system perspective, it is likely that ATMPs will continue to be introduced in a small
-
Event: World Pharma Pricing and Market Access Congress
A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
